首页 / 院系成果 / 成果详情页

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology 期刊论文

编号：

73597F499A715F99F86DF2B0DA4CC0B2
作者：

Qi, Li#^[1]Li, Guiqing^[1];Li, Peipei^[1];Wang, Hongwei^[3,4];Fang, Xiaolong^[1,2];He, Tongchuan^[5];Li, Jingjing*^[1,2]
语种：

英文
期刊：

GENES & DISEASES ISSN：2352-4820 2024 年 11 卷 4 期 ; JUL
收录：
关键词：

Gendicine Gene therapy p53 mutation Recombinant p53 adenovirus TP53
摘要：

Genetic mutations in TP53 contribute to human malignancies through various means. To date, there have been a variety of therapeutic strategies targeting p53, including gene therapy to restore normal p53 function, mutant p53 rescue, inhibiting the MDM2-p53 interaction, p53-based vaccines, and a number of other approaches. This review focuses on the functions of TP53 and discusses the aberrant roles of mutant p53 in various types of cancer. Recombinant human p53 adenovirus, trademarked as Gendicine, which is the first anti-tumor gene therapy drug, has made tremendous progress in cancer gene therapy. We herein discuss the biological mechanisms by which Gendicine exerts its effects and describe the clinical responses reported in clinical trials. Notably, the clinical studies suggest that the combination of Gendicine with chemotherapy and/or radiotherapy may produce more pronounced efficacy in slowing tumor growth and progression than gene therapy/chemotherapy alone. Finally, we summarize the methods of administration of recombinant human p53 adenovirus for different cancer types to provide a reference for future clinical trials.
推荐引用方式
GB/T 7714：

Qi Li,Li Guiqing,Li Peipei, et al. Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology [J].GENES & DISEASES,2024,11(4).
APA：

Qi Li,Li Guiqing,Li Peipei,Wang Hongwei,&Li Jingjing.(2024).Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology .GENES & DISEASES,11(4).
MLA：

Qi Li, et al. "Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology" .GENES & DISEASES 11,4(2024).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：4  下载次数：0

分享到：

浏览次数：4

下载次数：0

打印次数：0